Apimeds Pharmaceuticals US, Inc.

Apimeds Pharmaceuticals US, Inc. is a clinical-stage biopharmaceutical company focused on developing Apitox, a purified honeybee venom-based active pharmaceutical ingredient intended for intradermal administration. The company’s lead program is aimed first at inflammatory conditions, especially osteoarthritis, with multiple sclerosis identified as a longer-term potential indication. Apitox is licensed from Apimeds Korea for development and commercialization in the United States, and the company pays a sales royalty under that agreement. As a pre-commercial company, Apimeds is still dependent on regulatory approval, clinical development progress, and external financing to advance its product candidate.

1.31

1.31

— Apimeds Pharmaceuticals US, Inc.
%
Lead drug candidate100% Apitox is the company’s core product candidate, a bee venom-based API being developed for intradermal use.
Clinical development services0% Internal R&D, regulatory preparation, and product development activities supporting Apitox.
Licensed commercialization rights0% U.S. rights to develop, market, and sell Apitox under an exclusive license from Apimeds Korea.

Apimeds does not yet appear to have commercial customers because it is still in the clinical-stage development phase...

  • Regulatory and clinical stakeholdersprimary

    FDA, investigators, and trial partners that enable development and approval of Apitox.

  • Osteoarthritis patientsprimary

    The initial target patient group for Apitox if the product is approved for inflammatory pain management.

  • Physicians and treatment centerssecondary

    Healthcare providers that would prescribe or administer Apitox in a clinical setting.

  • Multiple sclerosis patientsemerging

    A longer-term potential patient segment if the company expands the label beyond osteoarthritis.

Apimeds Pharmaceuticals US, Inc. is based in the United States and is focused on developing and commercializing Apitox...

  • •United States is the primary development and future commercialization market
  • •South Korea is the source of the licensed product know-how and existing commercial precedent
  • •The company’s current operations are U.S.-centric and development-focused
  • •No country revenue breakdown is disclosed because the company is not yet commercial
  • •Cross-border licensing creates dependence on foreign IP and process expertise

The company’s strategy is to advance Apitox through the regulatory pathway and establish it as a treatment for...

01
Regulatory advancement of Apitoxshort-term

Approval is the key gate to any future revenue and determines whether the product can be commercialized in the U.S.

02
Liquidity and financing managementshort-term

The company has operating losses and needs capital to fund research, development, and commercialization activities.

03
Indication expansionmedium-term

Broader label potential could increase the commercial opportunity if the initial osteoarthritis program succeeds.

Apimeds is exposed to the core risks of clinical-stage biotechnology: regulatory failure, clinical development...

critical

Regulatory approval failure

Apitox cannot be commercialized in the U.S. without successful FDA review and approval.

Scope
Lead product candidate
Materiality
high
high

Insufficient financing

The company has incurred significant losses and depends on external capital to fund development.

Scope
Corporate liquidity
Materiality
high
high

Clinical efficacy or safety setbacks

Unexpected trial results could reduce the probability of approval or commercial viability.

Scope
Apitox development program
Materiality
high
medium

License dependence on Apimeds Korea

The U.S. rights to Apitox are licensed, so the company depends on the counterparty for underlying IP and economics.

Scope
Intellectual property and royalties
Materiality
medium
Convertible instruments
Can affect debt carrying value, interest expense, and reported losses
Development-stage expense recognition
Affects net loss and operating expense trends
Equity issuance from IPO
Affects EPS, equity balances, and liquidity presentation

Apogee Therapeutics, Inc.

APGE · Biological Products, (No Diagnostic Substances)

Aptose Biosciences Inc.

APTOF · Biological Products, (No Diagnostic Substances)

Aptevo Therapeutics Inc.

APVO · Pharmaceutical Preparations

AIM ImmunoTech Inc.

AIM · Biological Products, (No Diagnostic Substances)

Upstream Bio, Inc.

UPB · Pharmaceutical Preparations

Amylyx Pharmaceuticals, Inc.

AMLX · Pharmaceutical Preparations

: 11/08/2026